Advanced in Pernicious Anemia

Guillaume Roquin

Angers, FR 
Advanced in Pernicious Anemia
Angers, FR 
OverviewLocationsClinical Research

Overview

Guillaume Roquin practices in Angers, France. Mr. Roquin is rated as an Advanced expert by MediFind in the treatment of Pernicious Anemia. His top areas of expertise are Pernicious Anemia, Neuroendocrine Tumor, Insulinoma, and Vitamin B12 Deficiency Anemia.

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Pernicious Anemia.

Gender
Male

Locations

Angers, France
Other Locations
Lyon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Folfiri+Bevacizumab, Folfiri
Study Phase: Phase 2
Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer
Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Irinotecan Liposomal Injection, 5-FU/LV, Nab-Paclitaxel, Gemcitabine
Study Phase: Phase 2
View 1 Less Clinical Trial

15 Total Publications

Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC.
Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC.
Journal: ESMO open
Published: September 05, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Roquin's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile